Cobio Awarded $249,500 OEDIT Grant

We are proud to announce that we have been awarded a $249,500 Early-Stage Capital and Retention Grant from the Colorado Office of Economic Development and International Trade (OEDIT). The grant officially commenced in April 2024 and represents a significant milestone in our mission to advance bioscience innovation here in Colorado. 

The Early-Stage Capital and Retention Grant is part of OEDIT's Advanced Industries Accelerator Program, designed to help Colorado-based technology businesses develop and commercialize advanced technologies that are created or manufactured in Colorado. Awards are highly competitive, requiring rigorous review by independent industry, technical, and financial experts, with final approval by the Colorado Economic Development Commission. Being selected among the year's cohort is an honor! 

This funding will accelerate the isolation of new bacteriophages for use in the development of our diagnostic platform for same-shift, direct-from-specimen pathogen ID, AST, and MIC determination. The award enables our team to create a phage bank directed at the ESKAPE pathogens, bringing us closer to delivering new diagnostic capabilities to fight growing antimicrobial resistance. 

We are grateful to OEDIT, the Colorado Economic Development Commission, and the broader Colorado bioscience community for their continued investment in companies like ours. Colorado's life sciences ecosystem is one of the most dynamic in the country, and we are proud to contribute to its growth and global competitiveness.